Microfer

Quick links to important sections

Microfer

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Microfer

Property Description
Active Ingredient Ferrous Sulfate (FeSO4)
Form Oral tablets, capsules, or liquid (drops/syrup)
Pharmacological Class Haematinic / Iron Replacement Product
General Purpose Replenishing iron stores and supporting red blood cell function
Origin Synthetic Agent

What Type of Medicine is Microfer? (Identity and Classification)

Microfer is classified as a haematinic and an Iron Replacement Product, utilizing the active ingredient Ferrous Sulfate (FeSO4) to deliver elemental iron to the body. This medication is a synthetic agent and a single-entity product designed for the non-invasive oral route of administration. Ferrous Sulfate is a widely accepted standard form of oral iron supplementation, with its efficacy supported by decades of pharmacological practice and established medical reviews.

Differentiation is based on the compound itself: Ferrous Sulfate contains bivalent iron (Fe(II)), which is clinically recognized for its relatively consistent rate of gastrointestinal absorption compared to other iron salts, making it a foundational compound for correcting common deficiencies.


Composition and Available Forms (Substance and Delivery)

The core composition of Microfer relies on the Ferrous Sulfate salt, providing the necessary source of highly bioavailable iron. The compound is chemically manufactured, ensuring consistent elemental iron content across its various presentations. It is available in several oral forms, including standard tablets, capsules (sometimes with extended-release mechanisms), and oral liquid preparations like drops or syrups.

The availability of an oral liquid form is a key feature, making the product suitable for patient groups who cannot easily swallow solid medication, such as infants or young children.


What is Microfer's General Purpose? (High-Level Benefit)

The fundamental purpose of Microfer is to efficiently replenish iron stores within the body and support its oxygen transport system. The iron supplied by Ferrous Sulfate is an essential building block required for the production of hemoglobin, the critical protein within red blood cells responsible for carrying oxygen from the lungs to all tissues. This high-level benefit confirms the medicine directly supports the body's vital capacity to maintain overall oxygenation.

Regulatory References

  1. How to give your child liquid medicines | Great Ormond Street Hospital (NHS)

What side effects are possible with Microfer?

Possible Side Effects and Safety Information

The safety profile for Microfer, an intravenous iron replacement product, is structured by government regulatory bodies based on clinical trial data and post-marketing surveillance. This section outlines the documented adverse reactions and safety restrictions.


Documented Adverse Reactions

Side effects are classified by the frequency observed in clinical studies. Reactions primarily involve the gastrointestinal system, skin, and site of administration.

Classification Common Adverse Reactions (Most Frequent)
Frequency Nausea, rash, dizziness, hypertension, and injection site reactions (e.g., pain, discoloration).

Serious Adverse Reactions and Safety Constraints

Serious Hypersensitivity Reactions: The most critical risk is serious hypersensitivity (including anaphylaxis), which has been documented as life-threatening. Due to this risk, the drug is contraindicated in patients with a history of serious hypersensitivity to Microfer or its components.

Monitoring Requirement: All patients must be observed by trained personnel during and for at least 30 minutes after administration to promptly manage any hypersensitivity reactions. Immediate availability of emergency treatment is mandated.

Other Safety Risks:

  • Iron Overload: Excessive therapy can lead to hemosiderosis. Monitoring of iron parameters (serum ferritin and transferrin saturation) is required to prevent this risk, which is also a contraindication if already present.
  • Hypophosphatemia: Clinically significant drops in serum phosphate have been documented and may require additional monitoring.
  • Extravasation: Accidental leakage of the drug at the injection site may cause long-lasting brown skin discoloration.

Regulatory documents also caution against use in patients with severe infections or active liver disease, and note specific safety considerations regarding use during pregnancy.

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented manifestations of Ferrous Sulfate (Microfer) overdose and regulatory mandates for seeking emergency care.


Documented Overdose Presentations and Risks

Domain Regulatory Information
Documented Presentations Gastrointestinal toxicity (severe stomach pain, bloody vomiting, tarry stool), systemic effects (hypotension, tachycardia, metabolic acidosis), and neurological symptoms (lethargy, convulsions, coma).
Severe Outcomes Progression can lead to shock, hepatic necrosis, pulmonary oedema, and eventual death. Long-term complications may include gastrointestinal obstruction.
Pediatric Vulnerability Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Overdosage is explicitly noted as particularly dangerous to young children.

Required Emergency Action

Immediate medical attention is crucial. Regulatory labeling requires individuals to seek emergency medical attention immediately or call a doctor or poison control center if overdosage is suspected or if the product has been accidentally swallowed by anyone, especially a child. Immediate medical support is required for airway, breathing, and circulation (ABC). The specific antidote used for systemic toxicity is Deferoxamine, a chelating agent. Monitoring of serum iron concentrations and vital signs is required during management.

The official overdose profile mandates immediate help-seeking due to the rapid, severe progression of iron toxicity, which affects multiple systems and carries a high risk of fatality, particularly in young children.

Therapeutic Uses of Microfer

Microfer is an iron replacement product containing Ferrous Sulfate, used to address the clinical and symptomatic consequences of iron deficiency. This type of therapy is primarily used to treat or prevent iron-deficiency anemia when dietary intake is insufficient or iron loss is excessive.

Alleviating Anemia-Related Fatigue and Weakness

The medication is commonly used to help manage symptoms that create noticeable physiological strain, such as significant fatigue and muscle weakness that interfere with daily functioning. By supporting the oxygen-carrying capacity of the blood, it provides support that helps ease the overall symptom burden of energy depletion and assists with maintaining functional stability.


Managing Circulatory and Physical Manifestations

Microfer is applied in clinical settings that involve acute or disruptive symptom patterns of anemia, including the heart's compensatory efforts like palpitations and shortness of breath during exertion. It is applied in addressing deficiency-related signs such as restless legs syndrome or unusual pallor, and contributes to improved comfort during symptomatic periods.


Prophylactic Use in High-Demand Scenarios

Microfer is relevant for conditions associated with increased physiological stress, notably pregnancy, periods of rapid growth, and chronic blood loss states. In these scenarios, it is commonly used when supportive symptom management is appropriate to maintain sufficient iron levels.


Quick Fact: Symptomatic Support for Iron Deficiency

Microfer is commonly used to address the three primary symptomatic categories of iron deficiency: energy depletion (fatigue/weakness), circulatory compensation (palpitations/breathlessness), and neurological/physical manifestations (restless legs/pallor).

Regulatory References

  1. MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Microfer is an oral iron replacement product; its use is defined by strict regulatory criteria based on specific patient populations and medical conditions.

Prohibited Populations (Contraindications)

Use is contraindicated in patients with established iron overload disorders, including hemochromatosis and hemosiderosis. The medicine must not be used by individuals receiving repeated blood transfusions or those with hemolytic anemia unless a co-existing iron deficiency is documented. Furthermore, Microfer is contraindicated in patients with severe gastrointestinal pathologies, such as peptic ulceration, ulcerative colitis, or regional enteritis.

Conditional Use and Cautions

Caution is required for individuals with pre-existing gastrointestinal diseases or disorders affecting iron storage or absorption. For pregnant females, use during the first 12 weeks requires specific medical recommendation, though it is generally acceptable later in pregnancy for iron deficiency prevention. Lactating females are advised to seek the guidance of a health professional before use.

Age-Group Restrictions

Adults are the standard eligible population. Use in children requires the direction of a physician. The official labeling carries an explicit warning that accidental overdose in children younger than six years is a leading cause of fatal poisoning, strictly mandating that the product be kept out of their reach.

What should I know about interactions with other medicines?

The official regulatory profile for Microfer (Ferrous Sulfate) is defined by pharmacokinetic interactions that primarily result in reduced systemic exposure for either the iron preparation or a co-administered medicine.

Interaction Category Documented Interacting Entities
Exposure-Altering Drugs Levothyroxine, Tetracycline and Quinolone antibiotics, Bisphosphonates, Levodopa, Antacids.
Pharmacodynamic Chloramphenicol
Supplement/Food Vitamin C (increase); Zinc, Calcium, Coffee, Tea, Milk (decrease).

Interaction-Related Constraints and Requirements

The most frequent interaction is the reduction in absorption of the co-administered drug or the iron product itself. The regulatory documents specify that co-administration of oral iron and parenteral iron is formally prohibited. To mitigate the common absorption interaction risk, administration of Microfer must be separated from certain drugs. For instance, Tetracycline antibiotics require a separation of at least two hours before or three hours after taking the iron. Other interacting medicines, including Levothyroxine and Bisphosphonates, typically require a minimum separation of two to four hours to maintain therapeutic concentration levels. These timing restrictions are mandatory to minimize the risk of reduced drug effectiveness. The pharmacodynamic interaction with Chloramphenicol is officially documented as delaying plasma iron clearance.

Mechanism of Action

Microfer's mechanism is based on the introduction and subsequent utilization of iron to influence the process of red blood cell production.

Exogenous Iron Dissociation and Transfer

The iron complex dissociates within the body's reticuloendothelial system, specifically within macrophages, releasing ferric iron ( Fe^3+). This ferric iron then binds to the plasma transport protein transferrin. This process directly modifies the availability of circulating iron, bypassing the standard, rate-limiting steps of gastrointestinal absorption. The immediate system-level physiological consequence is a measurable increase in the levels of serum iron.


Intracellular Iron Utilization for Hemoglobin Synthesis

This mechanistic domain covers the downstream cascade of iron utilization. The transferrin-bound iron is transported to its primary biological target, erythroid precursor cells in the bone marrow, via the transferrin receptor. Within the cytosol of these cells, the iron is released and incorporated into the porphyrin ring structure of heme. Heme subsequently combines with globin chains to form hemoglobin. This incorporation step drives hemoglobin synthesis within the erythroid lineage, influencing the overall systemic process of erythropoiesis.

Dosage and Administration Information

Microfer (Ferrous Sulfate) is administered exclusively via the oral route using available forms that include tablets, extended-release capsules, and oral liquids. The medication must be swallowed whole with water and must not be chewed, crushed, or sucked to preserve the formulation's intended release profile.

The standard adult regimen for treatment generally involves a daily dose of 100 to 200 mg elemental iron, which is often delivered as a 200 mg ferrous sulfate salt tablet in divided doses up to three times per day. For prophylactic use, a single daily dose of 65 mg elemental iron is typically administered. Pediatric use follows specific weight-based guidelines, with oral liquid forms preferred for infants and young children.

To ensure optimal absorption, the medication is ideally taken on an empty stomach, approximately one hour before or two hours after a meal. However, the dose may be taken with or after food to manage practical tolerance issues. A critical administration requirement is the 2-hour separation of Microfer intake from consuming certain inhibitory substances such as antacids, tea, coffee, milk, or dairy products.

Therapy is not short-term; the duration of use is typically constrained by the need to replenish iron stores. Treatment generally continues for 3 to 6 months after the patient’s blood parameters have normalized. If a dose is missed, it is generally advised to skip the forgotten dose if the next one is due soon, and never take two doses at one time.

Recent Clinical Evidence

Microfer: Recent Clinical Evidence

This section summarizes the structure of the research base for Ferrous Sulfate (the active ingredient in Microfer) as evaluated by regulatory and scientific bodies. This overview is non-advisory and focuses only on study patterns.


Evidence for Iron-Deficiency Anemia (IDA)

The foundational research consists primarily of short-term Randomized Controlled Trials (RCTs) and systematic reviews that examined Ferrous Sulfate versus comparators. Studies explored data related to iron status in the body, focusing on hematologic biomarkers like Hemoglobin and Serum Ferritin. Researchers also monitored outcomes reflecting daily functioning, such as patient-reported fatigue and muscle weakness. Findings describe patterns observed in the cohorts, but long-term effects on the durability of iron stores are not fully established. A key research limitation is that data for certain groups remain insufficient because study dropout due to gastrointestinal events was common, creating methodological complexities.


Evidence in Special Populations and Prophylaxis

Ferrous Sulfate was evaluated in research exploring outcomes related to the incidence of iron deficiency in conditions associated with increased physiological stress, such as during pregnancy. Outcomes examined included measurements related to the incidence of Maternal Iron Deficiency Anemia and the incidence of low birth weight. Separate research has also been conducted on infants and young children and specific comorbid conditions like Inflammatory Bowel Disease (IBD).


Research Gaps and Uncertainty

A review of the evidence highlights where certainty remains low. For preventative use in specific asymptomatic groups, authoritative reviews have noted that evidence quality varies across studies. Furthermore, most published research was evaluated in short-term settings, meaning limited long-term effects are not fully established. The research helps show what has been observed so far, but study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Iron Deficiency Anemia (IDA) - MedlinePlus Medical Encyclopedia
  2. Recommendations on Iron Supplementation and Screening in Pregnant Persons (Conceptual Source for Prophylaxis Evidence)
  3. Ferrous Sulfate Regulatory Assessment Report (Conceptual Source for Evidence Scope)

Frequently Asked Questions (FAQ)

Common questions about Microfer (FAQ)


Q: Can Microfer be crushed or split if swallowing is difficult?

A: Official administration instructions for Microfer formulations, especially extended-release or coated tablets, state that they must be swallowed whole and should not be chewed, crushed, or split. According to regulatory documents, this is specified to maintain the product's intended release profile.


Q: Can Microfer change the color of my stools?

A: Yes, Microfer may cause stools to appear darker than usual, or black. Regulatory labeling indicates this is a common occurrence with oral iron supplements. The product information also advises that this change should be noted, as it may sometimes be confused with symptoms of gastrointestinal bleeding.


Q: Is it safe to take Microfer with my daily multivitamin?

A: Official information indicates that Microfer can interact with certain ingredients commonly found in multivitamins, such as calcium, zinc, and other minerals, which can potentially reduce iron absorption. Official guidance often suggests separating the intake of Microfer and these types of supplements by several hours.


Q: What are the typical storage conditions for Microfer?

A: Official labeling advises that Microfer should generally be stored at controlled room temperature, typically between 20^circC and 25^circC (68^circF and 77^circF), away from moisture and excessive heat. A critical safety statement requires keeping all iron-containing products securely out of the reach of children.


Q: Is Microfer known to interact with caffeine?

A: Regulatory guidance often recommends separating the use of iron supplements from beverages like coffee and tea, as they can contain compounds that inhibit iron absorption. The official guidance generally advises a separation of approximately two hours before or after taking Microfer.


Q: How quickly should I expect to feel a difference after starting Microfer?

A: The time required to feel a difference varies by individual. Regulatory patient information generally states that some improvement in symptoms may begin within a few weeks. However, the duration typically needed for iron stores to be replenished is three to six months.


Q: What are the most common side effects of Microfer?

A: According to official product labeling, the most commonly reported side effects of Microfer are gastrointestinal issues. These often include nausea, vomiting, constipation, diarrhea, and general stomach discomfort, and they are sometimes related to the dose taken.


Q: Who are the people generally ineligible to use Microfer?

A: Official product information states that Microfer is generally not recommended for people who have conditions involving iron overload, such as hemochromatosis. It is also typically contraindicated for patients whose anemia is not caused by iron deficiency, and is often contraindicated for individuals with certain gastrointestinal diseases.


Q: Do I need a prescription from a doctor to get Microfer?

A: Ferrous sulfate, the active ingredient in Microfer, is widely available in many formulations as an over-the-counter (OTC) supplement. However, certain higher strengths, specialized liquid formulations, or treatment plans may require a prescription from a healthcare provider.


Q: Is there a generic version of Microfer available?

A: Yes, ferrous sulfate is the chemical name for the active ingredient in Microfer and is a widely available generic drug. It can be purchased under its chemical name or various generic brand names.


Q: Has Microfer been studied in pregnant women?

A: Ferrous sulfate is a product commonly used during pregnancy to prevent or treat iron deficiency, as advised by a healthcare professional. Official labeling states that treatment in early pregnancy should only be under specific medical guidance, while use in later pregnancy is generally accepted.


Q: Can older adults use Microfer safely?

A: Microfer is used in older adults, but regulatory guidance may suggest starting with a lower dose to help minimize the risk of gastrointestinal side effects. Official labeling notes that close monitoring is advised in this age group.


Q: Can children use Microfer?

A: Microfer is available in specific dosage forms and is used in children under the direction of a healthcare provider. The official labeling contains a serious warning that accidental overdose of iron-containing products is a leading cause of fatal poisoning in young children, highlighting the critical need for safe storage of iron products.


Q: What kind of research supports the use of Microfer?

A: Research supporting the use of Microfer (ferrous sulfate) includes clinical studies and systematic reviews. These studies primarily examine its effectiveness in treating iron deficiency anemia by improving objective blood iron parameters and helping to replenish the body’s iron stores.


Q: Is it possible to take too much Microfer?

A: Yes, taking more than the prescribed or recommended amount of Microfer can lead to an overdose. Regulatory warnings indicate that iron overdose is classified as a medical emergency, especially in children, and may be toxic or fatal if not treated promptly.


Q: Is Microfer suitable for people with certain food allergies?

A: Microfer’s active ingredient is generally not an allergen, but patients with known allergies should review the inactive ingredients (excipients) list of their specific formulation. Official documents note that if a patient is allergic to any component of the tablet or liquid, they should not use that product.


Q: What is the difference between Microfer and IV iron treatments?

A: Microfer is an oral treatment, which is typically the first-line and most cost-effective option for iron deficiency. Intravenous (IV) iron treatments are generally reserved for patients who cannot tolerate or absorb oral iron, or for those who require a very rapid correction of their iron status.

How should Microfer be stored and disposed of?

How to Store and Dispose of Microfer

The storage and disposal instructions for Microfer (Ferrous Sulfate) are set by regulatory bodies to maintain product quality and ensure safety.


Official Storage Requirements

Microfer must be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). The product must be kept in its original, tightly closed container in a dry place and protected from excessive heat, light, and moisture. It is required that this medication not be frozen.


Child Safety and Disposal

All forms of Microfer must be stored out of the sight and reach of children due to the serious risk of accidental iron overdose. Unused or expired medication should not be flushed down the toilet or poured down a drain. Disposal should follow official guidelines, utilizing community drug take-back programs as the preferred method to safely discard the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Microfer found in:

A-Z Index: